Selective M4 antagonism potentiates L-DOPA-induced dyskinesia in MPTP-treated common marmosets
Objective: To determine the role of M4 muscarinic receptors in the expression of L-DOPA-induced dyskinesia (LID) and dystonia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. Background:…Tear fluid as potential biomarker for the diagnosis of Parkinson’s disease
Objective: This study compares tear fluid proteome in patients with idiopathic Parkinson´s disease (PD) and age-matched healthy controls (HC) to characterize disease-related proteomic changes and…PERFORM: Controlled study in fluctuating PD patients examining the effects of motor state on the outcomes resulting from a structured physical therapy (PT) program
Objective: To determine if outcomes following a PT program are improved if PT sessions are conducted while PD patients are in an on motor state…Duodopa treatment experience in Oradea
Objective: We want to present our results in Duodopa treatment for advanced Parkinson's disease (PD). Background: A center for advanced PD was created in our…Swallowing difficulties in patients with Parkinson’s disease and Parkinsonian syndromes
Objective: To analyze the frequency and severity of swallowing difficulties in patients with Parkinson's disease (PD) and Parkinsonian syndromes. Background: Swallowing difficulties are common in…Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: Nilotinib is FDA-approved for the treatment of chronic myeloid leukemia (CML) at 800mg oral dose twice daily. We examined the effects of lower doses…Safety of opicapone in fluctuating Parkinson’s disease patients: Results of the 1-year extension of study BIPARK I
Objective: Evaluate the safety of opicapone (OPC) in Parkinson's disease patients with motor fluctuations enrolled in the 1-year extension of study BIPARK I. Background: OPC,…The efficacy of tremor detection and suppression device in intractable rest tremor in patients with Parkinson’s disease
Objective: This study was designed to determine the efficacy of the Tremor Detection and Suppression device (TDS) as a therapeutic option in PD patients with…Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany
Objective: To evaluate the duration of treatment (DOT) and safety of apomorphine continuous subcutaneous infusion (CSI) in patients with advanced PD inscribed in a managed…Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…
- 1
- 2
- 3
- …
- 207
- Next Page »